In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Application for cardiac self-Improvement(ANSIM), a randomized controlled trial: 9-month clinical outcome

Session Poster Session 2

Speaker Ji Bak Kim

Congress : EuroPrevent 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P519

Authors : J B Kim (Bucheon,KR), SK Lee (Hwaseong,KR), SJ Lee (Seoul,KR), SE Shine (Seoul,KR), JH Ahn (Seoul,KR), JE Lee (Seoul,KR), HG Jeong (Seoul,KR), SJ Lee (Seoul,KR), KH Jung (Seoul,KR), HY Park (Seoul,KR), YH Song (Seoul,KR), EJ Kim (Seoul,KR)

15 views

Authors:
J B Kim1 , SK Lee2 , SJ Lee3 , SE Shine3 , JH Ahn4 , JE Lee4 , HG Jeong5 , SJ Lee5 , KH Jung6 , HY Park6 , YH Song6 , EJ Kim3 , 1Sejong General Hospital, Division of Cardiology, Department of Internal Medicine - Bucheon - Korea (Republic of) , 2Dongtan Sacred Heart Hospital, Division of Cardiology - Hwaseong - Korea (Republic of) , 3Korea University Guro Hospital, Cardiovascular Center - Seoul - Korea (Republic of) , 4Ewha University, Department of Health Management - Seoul - Korea (Republic of) , 5Korea University Guro Hospital, Department of Psychiatry - Seoul - Korea (Republic of) , 6Hanmi Healthcare - Seoul - Korea (Republic of) ,

Citation:

Background : Despite strong evidence, cardiac rehabilitation (CR) programs are severely underutilized. As the smartphone penetration rate has raised sharply, smartphone application based CR is getting attention as a promising alternative to traditional CR.

Purpose: This study aims to test the effects of patient-specific messaging smartphone application for patients with proven coronary artery disease (CAD) to enhance self-management of cardiovascular (CV) risk factors

Methods: The application for self-improvement (AnSim) trial was a single-blind, multicenter, randomized, controlled trial that recruited 120 patients who underwent percutaneous coronary intervention in our hospitals between December 2016 and April 2018. The patients were randomly assigned to intervention group (n=60) or control group (n=60), and patients in the intervention group (n=60) received 6 messages per week for 6months in addition to usual care. The Heart Keeper application developed by the Korean society of cardiology was commonly applied to both groups. The primary endpoint is a change in blood pressure at the 6th month. Secondary clinical endpoints include other CV risk factors, behavioral change, self-efficacy, quality of life, and satisfaction for the applications. Each variable will be re-evaluated at the 9th month to investigate the sustainability of changes after the intervention.

Result: At 6 months and 9 months, there was no significant difference in blood pressure between the two groups. (6 months: 124.1±16.5 vs 125.3±13.1, p-0.683 ; 9months: 126.8±14.4 vs 127.0±14.0, p=0.943) There were no significant differences between the two groups in other single variables such as body weight, blood glucose, total cholesterol level, and low-density lipoprotein cholesterol. When compares within the intervention group, The achieving rate for combined risk factor control (achieved target levels for 4 or more key risk factors among body weight, blood pressure, blood glucose, lipid level, and smoking cession) at 9 month was higher in the top 50% message user than lower 50% (48.4% vs. 13.8% , p=0.05)

Conclusion: Among patients with coronary heart disease, the use of a smart phone messaging service for CV risk factor did not show a short-term effect at 6th month. But at 9 month, it seems to be helpful for long term maintenance of CV risk factor control for patients with high application utilization.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are